Drug intelligence / Profile preview

CTL-DISC02

Development stage: Preclinical
Lead developer: CatalYm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CTL-DISC02 is a discovery-stage therapeutic program being developed by CatalYm, focusing on the modulation of Growth Differentiation Factor 15 (GDF-15) for the treatment of autoimmune disorders. GDF-15 is a stress-induced cytokine and a member of the TGF-beta superfamily that plays a significant role in immune homeostasis, inflammatory responses, and cell survival. While CatalYm's lead clinical candidate, visugromab, is designed to neutralize GDF-15 to reverse immunosuppression in the tumor microenvironment, CTL-DISC02 leverages GDF-15 biology to address the dysregulated immune signaling characteristic of autoimmune diseases. The program aims to utilize the company's expertise in GDF-15-directed antibodies to develop novel treatments that can restore immune balance and reduce chronic inflammation.

Other names: CatalYm GDF-15 autoimmune program

Targets

GDF15 (Growth differentiation factor 15)

Beyond the preview

Go deeper on CTL-DISC02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTL-DISC02.

Explore the full profile